In the present study, we developed anti-TGF-β1 aptamer, APT-β1-OMe-P, and revealed that TGF-β1-specific inhibition in xenograft model enhanced anti-tumor effect of gefitinib on cancer repopulation after withdrawal in combination therapy. The gene discussed is TGFB1; the disease is cancer.